Table 5.
Prognostic analysis in Parkinson's disease cohort, period June-September 2020.
| Parkinson's disease developing disease-specific outcomes | Parkinson's disease not developing disease-specific outcomes | P | |
|---|---|---|---|
| N | 38 | 709 | |
| Mean Age, yrs (SD, range) | 76.8 (8.0, 59–88) | 75.1 (9.6, 40–96) | 0.283 |
| Mean Age at onset, yrs (SD, range) | 67.1 (8.2, 48–81) | 66.2 (10.6, 29–89) | 0.607 |
| Age distribution, n (%) | 0.395 | ||
| 40–49 yrs | 0 (0.0) | 13 (1.8) | |
| 50–59 yrs | 1 (2.6) | 38 (5.4) | |
| 60–69 yrs | 6 (15.8) | 130 (18.3) | |
| 70–79 yrs | 11 (29.0) | 268 (37.8) | |
| 80–89 yrs | 20 (52.6) | 240 (33.9) | |
| ≥90 yrs | 0 (0.0) | 20 (2.8) | |
| Sex, n (%) | 0.215 | ||
| Male | 26 (68.4) | 413 (58.3) | |
| Female | 12 (31.6) | 296 (41.7) | |
| District, n (%) | 0.512 | ||
| Bologna | 19 (50.0) | 312 (44.0) | |
| Reno | 4 (10.6) | 86 (12.1) | |
| Pianura Est | 10 (26.3) | 120 (16.9) | |
| Pianura Ovest | 3 (7.9) | 81 (11.4) | |
| Appennino | 1 (2.6) | 57 (8.1) | |
| San Lazzaro | 1 (2.6) | 53 (7.5) | |
| Disability | 0.002 | ||
| Yes | 17 (44.7) | 159 (22.4) | |
| Charlson index, n (%) | 0.084 | ||
| 0 | 28 (73.6) | 584 (82.4) | |
| 1 | 2 (5.3) | 61 (8.6) | |
| 2 | 6 (15.8) | 44 (6.2) | |
| ≥3 | 2 (65.3) | 20 (2.8) | |
| Comorbidities, n (%) | |||
| Myocardial infarction | 0 (0.0) | 11 (1.6) | 0.999 |
| Congestive heart failure | 2 (5.3) | 35 (4.9) | 0.712 |
| Peripheral vascular disease | 0 (0.0) | 5 (0.7) | 0.999 |
| Cerebrovascular disease | 1 (2.6) | 17 (2.4) | 0.614 |
| Dementia | 1 (2.6) | 29 (4.1) | 0.999 |
| Chronic pulmonary disease | 3 (7.9) | 7 (1.0) | 0.011 |
| Peptic ulcer disease | 1 (2.6) | 2 (0.3) | 0.145 |
| Liver disease | 0 (0.0) | 1 (0.1) | 0.999 |
| Diabetes | 1 (2.6) | 20 (2.8) | 0.999 |
| Renal disease | 2 (5.3) | 12 (1.7) | 0.156 |
| Any malignancy | 4 (10.5) | 32 (4.5) | 0.104 |
| Clinical features at onset, n (%) | |||
| Unilateral | 34 (89.5) | 580 (81.8) | 0.281 |
| Bilateral | 4 (10.5) | 129 (18.2) | |
| Tremor (yes) | 27 (79.4) | 446 (71.6) | 0.323 |
| Bradykinesia (yes) | 30 (100.0) | 484 (79.5) | 0.002 |
| Hoehn and Yahr scale at latest observation | |||
| Mean (SD) | 2.9 (0.9) | 2.5 (1.0) | 0.022 |
| Score 4–5, n (%) | 8 (21.1) | 120 (16.9) | 0.511 |
| Drug treatment, n (%) | 0.487 | ||
| No therapy | 3 (7.9) | 68 (9.6) | |
| Levodopa only | 15 (39.5) | 349 (49.2) | |
| Dopaminergic only or IMAO B only | 2 (5.3) | 25 (3.5) | |
| Any combination of drugs | 18 (47.3) | 267 (37.7) | |
| Change in the number of any outpatient visit (2020 vs. 2019), n (%) | 0.563 | ||
| No change | 12 (31.6) | 246 (34.7) | |
| Reduction | 23 (60.5) | 374 (52.8) | |
| Increase | 3 (7.9) | 89 (12.6) | |
| Change in the number of neurologic outpatient visit (2020 vs. 2019), n (%) | 0.999 | ||
| No change | 28 (73.7) | 431 (60.8) | |
| Reduction | 11 (29.0) | 207 (29.2) | |
| Increase | 4 (10.5) | 71 (10.0) | |
| Change in the number of physiotherapy visit/activity (2020 vs. 2019), n (%) | 0.051 | ||
| No change | 28 (73.7) | 611 (86.2) | |
| Reduction | 9 (23.7) | 79 (11.1) | |
| Increase | 1 (2.6) | 19 (2.7) | |
| Change in the number of non-urgent hospital admission (2020 vs. 2019), n (%) | 0.231 | ||
| No change | 35 (92.1) | 666 (94.0) | |
| Reduction | 1 (2.6) | 30 (4.2) | |
| Increase | 2 (5.3) | 13 (1.8) |